Navigation Links
Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
Date:2/3/2009

NEW BRUNSWICK, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma drug candidate, SNS-01. SNS-01 is a nano-encapsulated combination therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy, maximum tolerated dose and the feasibility of long-term intravenous administration of SNS-01, were performed at the University of Waterloo, Ontario, Canada.

The Company's anti-myeloma efficacy study in severe combined immune-deficient mice with human multiple myeloma subcutaneous tumors tested SNS-01 dosages ranging from 0.15 mg/kg to 1.5 mg/kg. In these studies, mice treated with a dose of either 0.75 mg/kg or 1.5 mg/kg both showed a 91% reduction in tumor volume and a decrease in tumor weight of 87% and 95%, respectively. For mice that received smaller doses of either 0.38 mg/kg or 0.15 mg/kg, there was also a reduction in tumor volume (73% and 61%, respectively) and weight (74% and 36%, respectively). All of the treated mice, regardless of dose, survived.

This therapeutic dose range provided the basis for an 8-day maximum tolerated dose study in which normal mice received two intravenous doses of increasing amounts of SNS-01 (from 2.2 mg/kg to 3.7 mg/kg). Body weight, organ weight and serum levels of liver enzymes were used as clinical indices to assess toxicity. A dose between 2.2 mg/kg and 2.9 mg/kg was well tolerated with respect to these clinical indices, and the survival rate at 2.9 mg/kg was 80%. Those mice receiving above 2.9 mg/kg of SNS-01 showed evidence of morbidity and up to 80% mortality. The 2.9 mg/kg threshold, twice the upper end of the therapeutic dose range, was therefore determined to be the maximum tolerated dose in mice.

The final study, a
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
2. Senesco Expands on Preclinical Multiple Myeloma Findings
3. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
4. SmartNow.com Announces the Appointment of Dr. Melina Jampolis as Chief Medical Officer
5. Carriage Services Announces Fourth Quarter Earnings Release And Conference Call Schedule
6. Weight Watchers Announces Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Hudsonville Ice Cream Announces Recall
8. American Dietetic Association Announces Agenda for Health Reform
9. Hologic Announces First Quarter Fiscal 2009 Operating Results
10. Arizona Heart Institute Announces FREE Public Forum Featuring Live Viewing of Surgical Procedures Via High-Definition (HD) Satellite
11. Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... As payers pledge to move the bulk ... next few years, they are testing various initiatives to ... care spending they control — involved. The March issue ... tracks some of the strategies proposed by industry ... organization (ACO)-type model. , One way to get specialists ...
(Date:3/3/2015)... OH (PRWEB) March 03, 2015 On ... amended complaint in the United States District Court for ... and Financial Freedom, as well as insurance companies Balboa, ... 24, 2015 in Case No. 3:14-cv-152.) , The Plaintiff, ... with insurance companies to force her to buy too ...
(Date:3/3/2015)... March 03, 2015 Risperdal lawsuits ... market the atypical antipsychotic medication continue to move ... court documents, the South Carolina Supreme Court upheld ... & Johnson’s Janssen Pharmaceuticals unit had deceptively marketed ... while the Court’s February 25th decision characterized the ...
(Date:3/3/2015)... 2015 Loma Linda University Health announced ... well being, it will be offering new, healthier choices ... , Over the past year, a cross-section of Loma ... dietary criteria, listening to vendors, sampling their products, and ... , Most recently, a food fair was held ...
(Date:3/3/2015)... Today, Steve Weatherford, current New York Giants ... announced the donation of their brains to science during ... Month. In an effort to raise awareness for the ... health, Rice and Weatherford spoke of their experiences on ... brain health a priority to avoid the consequences of ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:Steve Weatherford and Sidney Rice Reveal Donation for Brain Injury Awareness Month 2
... Leaders for ... World Malaria Day, World ... Bill, WASHINGTON, April 25 A volunteer nurse from,Zambia and ... to emphasize the importance of joint efforts in the,fight against malaria ...
... 24 Amneal Pharmaceuticals, LLC is,pleased to announce ... wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,to ... The,acquisition includes Interpharm,s facilities on Long Island, New ... technology and,processes., Amneal will use its strong ...
... Peddling Video That Does Not Show Attack ... Nurses Will Never Forget SEIU,s Violence, OAKLAND, ... brutal attack on a labor conference in Michigan April 12, ... that,does not show the violence ... as proof that the ...
... say , , THURSDAY, April 24 (HealthDay News) -- Women who ... connects the thighbone to the shinbone. Beyond the immediate pain ... that this type of injury may lead to another vexing ... Rochester, Minn., found that young women who had surgery to ...
... survival when compared to expensive lab tests , , THURSDAY, ... a second-line series of drugs for HIV/AIDS patients who ... the basis of sophisticated and expensive lab tests. , ... slightly affected if these decisions are based instead on ...
... SC, April 24 /PRNewswire/ - Ron Nabors, Chief Executive,Officer ... up with,religious, business and sports leaders in a new ... millions of deaths from,malaria, ahead of the first-ever inaugural ... year, malaria kills more than 1.5 million people in ...
Cached Medicine News:Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 2Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 3Health News:Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 3Health News:Women Risk Bone Loss After Knee Surgery 2Health News:Women Risk Bone Loss After Knee Surgery 3Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 2Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 3Health News:Executive Director of cbm US congratulates UN on Malaria Campaign 2
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... Today, the Partnership for Prescription Assistance ... research companies, unveiled a redesigned website ... and caregivers with faster, easier access to information ... assistance programs. Since its launch ... engage, educate and empower patients and caregivers to ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2
... TAXUS(R) Element(TM) Stent now available in select markets ... (NYSE: BSX ) today announced the ... Coronary Stent System in select markets worldwide. ... chromium alloy engineered specifically for coronary stent applications ...
... Pa., May 18 MEDRAD Interventional(TM)/Possis(R) today announced ... the Paccocath(R) Technology closer to market as an ... the United States and Europe who suffer from ... selection of physician investigators for U.S. clinical trials ...
Cached Medicine Technology:Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 2Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 3Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 4Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 5
... a liver-specific contrast agent approved for sale ... introduction expands the Amersham Health portfolio to ... intravenously, TESLASCAN aids in the detection, localization, ... can begin within minutes of injection, and ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
... is the only isosmolar contrast medium (IOCM™) available ... that of blood, VISIPAQUE was designed for patient ... contrast medium formulated with sodium and calcium in ... received FDA approval for use in children over ...
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
Medicine Products: